TY - JOUR
T1 - eHealth
T2 - Individualization of Mesalazine Treatment Through a Self-managed Web-based Solution in Mild-to-moderate Ulcerative Colitis
AU - Pedersen, Natalia
AU - Thielsen, Peter
AU - Martinsen, Lars
AU - Bennedsen, Mette
AU - Haaber, Anne
AU - Langholz, Ebbe
AU - Végh, Zsuzsanna
AU - Duricova, Dana
AU - Jess, Tine
AU - Bell, Sally
AU - Burisch, Johan
AU - Munkholm, Pia
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Background: To individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease course. Methods: Prospective, open-label, web-guided study with 3 months mesalazine therapy among patients with mild-to-moderate ulcerative colitis. Once a week, patients completed the simple clinical colitis activity index (SCCAI) and registered fecal calprotectin (FC) on the web application: www.meza. constant-care.dk. SCCAI and FC were summed and resulted in a total inflammatory burden score (TIBS). Deep remission was defined as SCCAI≤1; FC = 0, and TIBS #1. Results: A total of 95 patients (62% females; median age 45 yr) were included in the study and allocated 4.8 g mesalazine per day. Of these, 82 (86%) patients were adherent to web therapy, completing 3 months of web-guided mesalazine therapy. Of the 82 adherent patients, 72 (88%) continued mesalazine and 10 (12%) needed rescue therapy. From weeks 0 to 12, patients had experienced a significant reduction in mean SCCAI (4.6 versus 1.6, P , 0.001), mean FC (437 versus 195, P , 0.001), and mean TIBS (6.7 versus 2.4, P , 0.001). Based on TIBS values (#1), the dose of mesalazine was reduced to 2.4 g in 25% of patients at week 3 in 50% of subjects at week 5 and in 88% of patients at week 12. Conclusions: Web-guided therapy with mesalazine in mild-to-moderate ulcerative colitis helps to individualize the dose and improve adherence to therapy. The study confirms mesalazine efficacy in mild-to-moderate UC, significantly improving TIBS values in majority of the patients.
AB - Background: To individualize treatment with mesalazine for ulcerative colitis relapses through a self-managed, web-based solution to optimize the short-term disease course. Methods: Prospective, open-label, web-guided study with 3 months mesalazine therapy among patients with mild-to-moderate ulcerative colitis. Once a week, patients completed the simple clinical colitis activity index (SCCAI) and registered fecal calprotectin (FC) on the web application: www.meza. constant-care.dk. SCCAI and FC were summed and resulted in a total inflammatory burden score (TIBS). Deep remission was defined as SCCAI≤1; FC = 0, and TIBS #1. Results: A total of 95 patients (62% females; median age 45 yr) were included in the study and allocated 4.8 g mesalazine per day. Of these, 82 (86%) patients were adherent to web therapy, completing 3 months of web-guided mesalazine therapy. Of the 82 adherent patients, 72 (88%) continued mesalazine and 10 (12%) needed rescue therapy. From weeks 0 to 12, patients had experienced a significant reduction in mean SCCAI (4.6 versus 1.6, P , 0.001), mean FC (437 versus 195, P , 0.001), and mean TIBS (6.7 versus 2.4, P , 0.001). Based on TIBS values (#1), the dose of mesalazine was reduced to 2.4 g in 25% of patients at week 3 in 50% of subjects at week 5 and in 88% of patients at week 12. Conclusions: Web-guided therapy with mesalazine in mild-to-moderate ulcerative colitis helps to individualize the dose and improve adherence to therapy. The study confirms mesalazine efficacy in mild-to-moderate UC, significantly improving TIBS values in majority of the patients.
U2 - 10.1097/MIB.0000000000000199
DO - 10.1097/MIB.0000000000000199
M3 - Journal article
C2 - 25248002
SN - 1078-0998
VL - 20
SP - 2276
EP - 2285
JO - Inflammatory Bowel Diseases
JF - Inflammatory Bowel Diseases
IS - 12
ER -